Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors

OGN Nov 2026 14.000 call (OGN261120C00014000) Stock Historical Prices & Data - Yahoo Finance

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon & Co. Estimates – NYSE:OGN

Organon & Co. (OGN) Stock Forecasts

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older

Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis

Why Organon (OGN) Is Getting Attention Today

Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device